Publications

  • 2026

    • Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial

      • , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • Nature Medicine
    • Genomic Surveillance of Lassa Virus through In-Country Sequencing, Guinea

      • , , , , , , , , , , , , , , , , , , , , ,
      • Emerg Infect Dis, Volume 32, Number 5
    • Evaluation of candidate reference materials for the harmonization of Lassa fever serology

      • , , , , , , , , , , , , , , , , , , , , ,
      • Emerging Microbes & Infections 2026, VOL. 15
    • Nosocomial outbreak of Lassa fever in Conakry, Guinea, 2022

      • , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • The Journal of Infectious Diseases
    • Two years of SARS-CoV-2 genomic surveillance capacity development in Guinea

      • , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • Scientific Reports 16, Article number: 11225 (2026)
    • ViMOP: a user-friendly and field-applicable pipeline for untargeted viral genome nanopore sequencing

      • , , , , , , , , , , , , , ,
      • Bioinformatics, Volume 42
  • 2025

  • 2024

    • rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches)

      • , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • BMC Med.
    • Presentation and Outcomes of Lassa Fever in Children in Nigeria: A Prospective Cohort Study (LASCOPE)

      • , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • J Pediatric Infect Dis Soc.
    • Virus Load Kinetics in Lassa Fever Patients Treated With Ribavirin: A Retrospective Cohort Study From Southern Nigeria

      • , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • Open Forum Infect Dis
  • 2023

  • 2022

  • 2021

    • Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks

      • , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • Nature. 2021 Sep;597(7877):539-543. doi: 10.1038/s41586-021-03901-9
    • The East African Community (EAC) mobile laboratory networks in Kenya, Burundi, Tanzania, Rwanda, Uganda, and South Sudan-from project implementation to outbreak response against Dengue, Ebola, COVID-19, and epidemic-prone diseases

      • , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • BMC Med. 2021 Jul 9;19(1):160. doi: 10.1186/s12916-021-02028-y
    • Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study

      • , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • Lancet Infect Dis. 2021 Jun;21(6):876-886. doi: 10.1016/S1473-3099(20)30737-4
    • Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study

      • , , , , , , , , , , , , , , , , , , , , , , , , ,
      • Lancet Glob Health. 2021 Apr;9(4):e469-e478. doi: 10.1016/S2214-109X(20)30518-0
    • Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin

      • , , , , , , , , , , , , , , , , , , ,
      • Trop Med Int Health. 2021 Jun;26(6):621-631. doi: 10.1111/tmi.13569
  • 2020

  • 2019

    • Tigray Orthohantavirus Infects Two Related Rodent Species Adapted to Different Elevations in Ethiopia

      • , , , , , , ,
      • Vector Borne Zoonotic Dis. 2019 Dec;19(12):950-953. doi: 10.1089/vbz.2019.2452
    • Lassa Virus in Pygmy Mice, Benin, 2016-2017

      • , , , , , , , , , , , , , ,
      • Emerg Infect Dis. 2019 Oct;25(10):1977-1979. doi: 10.3201/eid2510.180523
    • Phylogeography of Lassa Virus in Nigeria

      • , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • J Virol. 2019 Oct 15;93(21):e00929-19. doi: 10.1128/JVI.00929-19
    • Retrospective Cohort Study of Lassa Fever in Pregnancy, Southern Nigeria

      • , , , , , , , , , , , , , , , , , , , , , , ,
      • Emerg Infect Dis. 2019 Aug;25(8):1494–500. doi: 10.3201/eid2508.181299
    • Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational Study

      • , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • J Infect Dis. 2019 Jun 19;220(2):195-202. doi: 10.1093/infdis/jiz078
    • Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak

      • , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • Science. 2019 Jan 4;363(6422):74-77. doi: 10.1126/science.aau9343
  • 2018

  • 2017

    • Prevalence of Lassa Virus Disease (LVD) in Nigerian children with fever or fever and convulsions in an endemic area

      • , , , , , , , , , , , , , , , , ,
      • PLoS Negl Trop Dis. 2017 Jul 3;11(7):e0005711. doi: 10.1371/journal.pntd.0005711
    • Different features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infections

      • , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • PLoS Negl Trop Dis. 2017 May 30;11(5):e0005645. doi: 10.1371/journal.pntd.0005645
    • How to treat Ebola virus infections? A lesson from the field

      • , ,
      • Curr Opin Virol. 2017 Jun;24:9-15. doi: 10.1016/j.coviro.2017.03.003
    • Virus genomes reveal factors that spread and sustained the Ebola epidemic

      • , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • Nature. 2017 Apr 20;544(7650):309-315. doi: 10.1038/nature22040
    • Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus

      • , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • Genome Biol. 2017 Jan 19;18(1):4. doi: 10.1186/s13059-016-1137-3
    • Ebola Virus Persistence in Breast Milk After No Reported Illness: A Likely Source of Virus Transmission From Mother to Child

      • , , , , , , , , , , , , , , , , , , , , , , , , ,
      • Clin Infect Dis. 2017 Feb 15;64(4):513-516. doi: 10.1093/cid/ciw793
    • Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study

      • , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      • Lancet Glob Health. 2017 Jan;5(1):e80-e88. doi: 10.1016/S2214-109X(16)30243-1

Lab Group Duraffour-Pahlmann

Research Group Leader

Dr Meike Pahlmann

phone: +49 40 285380-588

fax: +49 40 285380-941

email: pahlmann@bnitm.de

  • [Translate to English:] Logo_Alexander_von_Humboldt_Stiftung
  • [Translate to English:] Logo Bundesministerium fuer Bildung und Forschung
  • [Translate to English:] Logo Bundesministerium Fuer Gesundheit
  • [Translate to English:] Logo CSSB
  • [Translate to English:] Logo DFG
  • [Translate to English:] Logo DZIF
  • [Translate to English:] Logo Emerge
  • [Translate to English:] Logo European Virus Archive goes global
  • [Translate to English:] Logo Federal Foreign Office
  • [Translate to English:] Logo GHP
  • [Translate to English:] Logo GPPEBHS
  • [Translate to English:] Logo iNext
  • [Translate to English:] Logo Jürgen Manchot Stiftung
  • [Translate to English:] Logo LCI
  • [Translate to English:] Logo Leibniz Gemeinschaft
  • [Translate to English:] Logo LFF Hamburg
  • [Translate to English:] Logo Pandora
  • [Translate to English:] Logo der Drugs for Neglected Diseases initiative, bestehend den aus drei orangefarbenen Großbuchstaben DND und einem kleinen i mit schwarzem Punkt.